[go: up one dir, main page]

WO2021022023A1 - Dispositifs, systèmes et procédés de réduction de grande ampleur des cytokines pro-inflammatoires dans le sang - Google Patents

Dispositifs, systèmes et procédés de réduction de grande ampleur des cytokines pro-inflammatoires dans le sang Download PDF

Info

Publication number
WO2021022023A1
WO2021022023A1 PCT/US2020/044223 US2020044223W WO2021022023A1 WO 2021022023 A1 WO2021022023 A1 WO 2021022023A1 US 2020044223 W US2020044223 W US 2020044223W WO 2021022023 A1 WO2021022023 A1 WO 2021022023A1
Authority
WO
WIPO (PCT)
Prior art keywords
inflammatory
blood
cytokines
cytokine
extracorporeal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2020/044223
Other languages
English (en)
Inventor
Craig P. Roberts
James A. Joyce
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigyn Therapeutics Inc
Original Assignee
Sigyn Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigyn Therapeutics Inc filed Critical Sigyn Therapeutics Inc
Priority to EP20757445.0A priority Critical patent/EP4007618A1/fr
Priority to CA3148773A priority patent/CA3148773A1/fr
Priority to JP2022506670A priority patent/JP2022542517A/ja
Publication of WO2021022023A1 publication Critical patent/WO2021022023A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3496—Plasmapheresis; Leucopheresis; Lymphopheresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A61M1/3475—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate with filtrate treatment agent in the same enclosure as the membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621—Extra-corporeal blood circuits
    • A61M1/3653—Interfaces between patient blood circulation and extra-corporal blood circuit
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/18—Apparatus therefor
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D63/00—Apparatus in general for separation processes using semi-permeable membranes
    • B01D63/02—Hollow fibre modules
    • B01D63/034—Lumen open in more than two directions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0413—Blood
    • A61M2202/0415—Plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0468—Liquids non-physiological
    • A61M2202/049—Toxic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/75—General characteristics of the apparatus with filters
    • A61M2205/7509—General characteristics of the apparatus with filters for virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/75—General characteristics of the apparatus with filters
    • A61M2205/7518—General characteristics of the apparatus with filters bacterial
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/26—Further operations combined with membrane separation processes
    • B01D2311/2626—Absorption or adsorption
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2313/00—Details relating to membrane modules or apparatus
    • B01D2313/40—Adsorbents within the flow path

Definitions

  • the present invention relates to devices, systems and methods to reduce the presence of inflammatory particles from blood and blood plasma.
  • Cytokines represent a family of more than 100 different immune response agents, which can exist in peptide, and protein forms. Included within the cytokine family are chemokines, interferons, interleukins, lymphokines and tumor necrosis factor. Cytokines may circulate freely in the bloodstream or be transported within or bound to the surface larger particles known as Cytovesicles.
  • cytokines An abnormal production or dysregulation of cytokines has been associated with a wide range of diseases.
  • the excessive chronic production of pro-inflammatory cytokines has been linked to atherosclerosis, cancer, cystic fibrosis, rheumatoid arthritis and neurological disorders, including Alzheimer’s disease.
  • An excessive acute production or dysregulation of pro-inflammatory cytokines may cause or con-tribute to life-threatening conditions, which include but are not limited to cytokine storm syndrome (CSS), virus induced cytokine storm, bacteria induced cytokine storm, acute respiratory distress syndrome (ARDS), cytokine release syndrome (CRS), graft-versus-host disease (GVHD), sepsis, systemic inflammatory response syndrome (SIRS), hepatic encephalopathy, acute kidney injury (AKI) and severe pneumonia. Beyond cytokine and CytoVesicles, circulating toxins and pathogens may contribute to the initiation or progression of acute inflammatory conditions.
  • CCS cytokine storm syndrome
  • ARDS acute respiratory distress syndrome
  • CRS cytokine release syndrome
  • GVHD graft-versus-host disease
  • SIRS systemic inflammatory response syndrome
  • AKI acute kidney injury
  • an extracorporeal system for the removal of inflammatory agents from blood includes a housing and a hollow fiber filter disposed within the housing.
  • the filter may include a plurality of pores sized and dimensioned to permit passage of inflammatory agents having a diameter between about 0.5 nanometers and 6000 nanometers.
  • the system further includes an adsorption component positioned inside the housing and outside the hollow fiber in an extra-lumen space.
  • the adsorption component is activated carbon, non-ionic exchange resin or ion exchange resin.
  • the inflammatory agents can include circulating cytokines, proteins with surface-bound cytokines, CytoVesicles with encapsulated cytokine cargos, CytoVesicles with surface bound cytokines, pathogens, endotoxins, and/or exotoxins.
  • a plurality of pores permit the inflammatory agents with diameters less than 0.60 microns to pass through the fiber walls and interact with the adsorption components. Additionally, the plurality of pores are sized and dimensioned to prevent a blood agent having a diameter greater than 0.60 microns to pass through the fiber walls and interact with adsorption components in the extra-lumen space, thereby preserving the integrity of the blood agents during filtration.
  • the activated carbon can be a coated or uncoated coconut shell granule.
  • the activated carbon can be a synthetic charcoal.
  • the adsorbent is at least one ion exchange resin or non ionic exchange resin.
  • the non-ionic exchange resin may be a non-ionic aliphatic ester resin, non-ionic polystyrene divinyl benzene resin, or other non-biologic adsorptive resins.
  • the at least one of said non-ionic aliphatic ester resins has an average surface area of approximately 500 m2/g, an average pore size of approximately 300-600 angstroms, and a mean particle diameter of 560 microns.
  • the non-ionic polystyrene divinyl benzene resins has an average surface area of approximately 700m2/g, and an average pore size of 300 angstroms, and a mean particle diameter from approximately 35 microns to approximately 120 microns.
  • the non ionic polystyrene divinyl benzene resins has an average surface area of approximately 600 m2/g, an average pore size of 100-400 Angstroms, and a mean particle diameter from approximately 300 microns to approximately 500 microns.
  • the activated carbon has a pore size distribution of a Micropore region of less than 100 Angstroms, a Mesopore region of between 100 and 1 ,000 Angstroms, and a Macropore region of greater than 1 ,000 Angstroms.
  • a method for treating a disease or disorder in an individual in need thereof includes providing an extracorporeal adsorptive toxin removal device.
  • the toxin removal device has a housing; a hollow fiber plasma filter having a number of pores sized between 200-6000 Angstrom; and an adsorbent positioned inside the housing and outside the fiber in the extra lumen space.
  • Plasma is filtered through the adsorptive toxin removal device to cause an inflammatory causing agent with a diameter less than 0.60 microns to pass through the pores.
  • the method also includes contacting the inflammatory causing agent with the absorbent; wherein the inflammatory causing agent binds to the adsorbent; and capturing the inflammatory causing agent in the adsorbent.
  • the capture of the inflammatory causing agent may prevent the agent from reentering circulation.
  • the inflammatory agent may be a pro-inflammatory cytokine such as IL-1 , TNF- a, IL-6, IL-1 1 , IL-8 , G-CSF, and GM-CSF, IL-3, IL-5, IL-7, IL-9, and transforming growth factor-b (TGF-b).
  • the inflammatory agent is an agent which contributes to cellular inflammation such as IL-1 , IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-10, IL-12, IL-13 interferons (IFNs), IFN-g inducing factor (IGIF), TGF-b, and TNF-a and -b.
  • the removal of inflammatory agents can treat a disease or disorder such as cytokine storm syndrome (CSS), virus induced cytokine storm, bacteria induced cytokine storm, acute respiratory distress syndrome (ARDS), cytokine release syndrome (CRS), graft-versus-host disease (GVFID), sepsis, systemic inflammatory response syndrome (SIRS), hepatic encephalopathy, acute kidney injury (AKI) and pneumonia.
  • a disease or disorder such as cytokine storm syndrome (CSS), virus induced cytokine storm, bacteria induced cytokine storm, acute respiratory distress syndrome (ARDS), cytokine release syndrome (CRS), graft-versus-host disease (GVFID), sepsis, systemic inflammatory response syndrome (SIRS), hepatic encephalopathy, acute kidney injury (AKI) and pneumonia.
  • CCS cytokine storm syndrome
  • ARDS acute respiratory distress syndrome
  • CRS cytokine release syndrome
  • GVFID graft-versus-host
  • the inflammatory agent is a biologic toxin.
  • the toxin is a bacterial endotoxin or exotoxin.
  • the bacteria may be gram positive or gram negative.
  • a method of simultaneously removing circulating cytokines, CytoVesicles, cytokine aggregates, and endotoxins from the blood of an individual may include: accessing an extracorporeal line to an individual’s circulatory system with a catheter; providing the extracorporeal system as disclosed herein, wherein the system has an inlet port and an outlet port; connecting the line to the inlet port; attaching a second extracorporeal line to the outlet port; controlling the flow of blood through the extracorporeal system with a pump; filtering the blood through the hollow fibers of the extracorporeal system; wherein filtering causes the circulating cytokines, CytoVesicles, cytokine aggregates, and endotoxins to pass through the pores and into the extra-lumen space; and contacting the filtered circulating cytokines, CytoVesicles, cytokine aggregates, and endotoxins with the adsorbent; wherein the adsorbent capture
  • FIG. 1 is a graphic representation of the cellular response to inflammation.
  • FIG. 2 is a perspective view of an embodiment of an extracorporeal device according to an aspect of the invention, wherein the housing is transparent to illustrate the hollow fibers and absorbent components.
  • FIG. 3 is a schematic representation of the use of an extracorporeal device for the filtration of plasma and capture of inflammatory causing agents.
  • Implementations of the technology described herein are directed generally to cytokine capture in the blood via an extracorporeal device. To facilitate an understanding of the various embodiments described herein, a number of terms are defined below.
  • a specific method of measuring the characteristic or property may be defined herein as well.
  • the measurement method should be interpreted as the method of measurement that would most likely be adopted by one of ordinary skill in the art given the description and context of the characteristic or property.
  • the value or range of values should be interpreted as being met regardless of which method of measurement is chosen.
  • Inflammation is a natural response of the human immune system to promote recovery from injury or defend against infection.
  • An important element of the host immune system is the release of molecular messengers known as cytokines, which regulate the response to disease, injury or infection, as well as mediate normal cellular processes in the body.
  • cytokines molecular messengers known as cytokines, which regulate the response to disease, injury or infection, as well as mediate normal cellular processes in the body.
  • the production of pro-inflammatory cytokines is a prerequisite for initiating the anti-infectious process, whereas their exacerbated production during severe inflammation may contribute to significant negative consequences.
  • unmet therapeutic needs include, but are not limited to the treatment of virus induced cytokine storm that underlies a broad-spectrum of viral pathogens (including COVID-19), bacteria induced cytokine storm, acute respiratory distress syndrome (ARDS) and acute forms of liver failure, including hepatic encephalopathy. Excessive cytokine production may also result from trauma, severe burns, acute pancreatitis, cancer immunotherapies, cancer cachexia, acute kidney injury and severe pneumonia.
  • virus induced cytokine storm that underlies a broad-spectrum of viral pathogens (including COVID-19), bacteria induced cytokine storm, acute respiratory distress syndrome (ARDS) and acute forms of liver failure, including hepatic encephalopathy.
  • ARDS acute respiratory distress syndrome
  • liver failure including hepatic encephalopathy.
  • Excessive cytokine production may also result from trauma, severe burns, acute pancreatitis, cancer immunotherapies, cancer cachexia, acute kidney injury and severe pneumonia.
  • Sepsis defined as a life-threatening organ dysfunction caused by a dysregulated host response, is perhaps the most prevalent condition resulting from the excess production of inflammatory cytokines.
  • the most prevalent“blood-in-blood-out” technologies are the Toraymyxin device developed by Toray Industries and the CytoSorb device developed by CytoSorbents Corporation. Both devices are market cleared in more than 40 countries. Toraymyxin has been safely administered to more than 150,000 patients and is the subject of more than 200 publications. CytoSorb has been safely administered to more than 80,000 patients.
  • Toraymyxin incorporates an antibiotic with a specificity to bind circulating endotoxin, which is a potent activator of inflammatory cytokines induced by bacterial infections.
  • Toraymyxin does not address cytokines and other inflammatory targets.
  • the CytoSorb device incorporates an adsorbent with pores that allow for the depletion of circulating cytokines below 5 nanometers in diameter, but does not address endotoxin or inflammatory particles larger than 5 nanometers in diameter.
  • the devices, systems and methods described herein provide for the simultaneous depletion of inflammatory particles and activators from the bloodstream.
  • targets may include, but are not limited to cytokines and endotoxin that circulate freely in the blood as well as inflammatory targets that have not been the focus of previous drug and device therapies. Included among these targets are cytokine aggregates and CytoVesicles that transport inflammatory cytokines and other mediators of inflammation.
  • Described herein is an extracorporeal technology that establishes a therapeutic modality to simultaneously address a broad-spectrum of particles that promote inflammatory diseases and conditions.
  • cytokines are defined to refer to a family of more than 100 different immunomodulation agents, which can exist in both peptide and protein forms. Included within the cytokine family are chemokines, interferons, interleukins, lymphokines and tumor necrosis factor.
  • an endotoxin is defined as any of a toxin present inside a bacterial cell and released when the cell disintegrates.
  • An endotoxin is a potent driver of inflammatory cytokine production that can result from a broad-spectrum of bacterial infections, including drug-resistant species.
  • a cytokine aggregate is defined as a formation (whose diameter exceeds 5 nanometers) comprised of two or more cytokines that have bound together in circulation.
  • CytoVesicles refer to particles (whose diameter exceeds 5 nanometers) which transport cytokines and other inflammatory cargos in the bloodstream. CytoVesicles are inclusive of microparticles (MPs) and microvesicles (MVs) classified as Extracellular Vesicles (EVs) with cytokines bound to their surface as well as EVs that transport cytokines as encapsulated cargo. CytoVesicle populations may also include platelet-derived MVs, endothelial-derived MVs and leukocyte-derived MVs, which are often prevalent in the blood of those suffering from acute and chronic inflammatory disorders.
  • MPs microparticles
  • MVs microvesicles classified as Extracellular Vesicles
  • EVs Extracellular Vesicles
  • CytoVesicle populations may also include platelet-derived MVs, endothelial-derived MVs and leukocyte-derived MVs, which are often prevalent in the blood of those suffering from acute and chronic
  • inflammatory particle refers to inflammatory cytokines, endotoxin, cytokine aggregates and CytoVesicles that circulate in biological fluids, including blood and blood plasma.
  • CytoVesicles include but are not limited to microparticles (MPs) and microvesicles (MPs) classified as Extracellular Vesicles (EVs) with cytokines bound to their surface as well as EVs that transport cytokines as encapsulated cargo.
  • CytoVesicle populations may also include platelet-derived MVs, endothelial-derived MVs and leukocyte- derived MVs, which are prevalent in the blood of those suffering from acute and chronic inflammatory disorders.
  • cytokine production is a vital component of the normal immune response to inflammation, trauma and infection; the overproduction or dysregulation of pro- inflammatory cytokines may contribute to the pathogenesis of a wide range of disease conditions.
  • the devices, systems and methods disclosed herein support the broad- spectrum reduction of freely circulating cytokines and CytoVesicles from blood. These include, but are not limited to, the following cytokines: IL-1 , TNF-alpha, IL-6, IL-1 1 , IL-8 and other chemokines, G-CSF, and GM-CSF.
  • This latter group can be subdivided into cytokines mediating humoral responses such as IL-4, IL-5, IL-6, IL-7, and IL-13, and those mediating cellular responses such as IL-1 , IL-2, IL-3, IL-4, IL-7, IL-9, IL-10, IL-12, interferons (IFNs), IFN-g inducing factor (IGIF), transforming growth factor-beta (TNF-b), and tumor necrosis factor alpha and beta.
  • CytoVesicles transport a wide range of biologically active cytokines that participate in concert with freely circulating cytokines to augment or promote acute and chronic pro- inflammatory disease conditions.
  • the simultaneous reduction of circulating cytokines and CytoVesicles establishes a novel therapeutic strategy to alleviate the symptoms or severity of disease conditions associated with the abnormal production or dysregulation of pro- inflammatory cytokines.
  • an extracorporeal device for the broad-spectrum reduction of pro-inflammatory cytokines in blood and/or plasma is provided.
  • the extracorporeal device can be a plasma separation device.
  • the extracorporeal device is an adsorptive toxin removal device, wherein blood or plasma is filtered through the device and inflammatory causing agents/toxins having diameters less than 0.60 microns can pass through pores and be bound, captured, and/or adsorbed by adsorbents in an extra-lumen space.
  • the device 100 comprises a cartridge housing 1.
  • housing 1 is transparent so as to reveal the internal components of the device 100. It will be appreciated, however, that the housing may be transparent, translucent, or opaque.
  • a hollow fiber filter 2 Disposed within the housing 1 is a hollow fiber filter 2 comprised of a plurality of hollow fibers having fiber walls and a plurality of pores. The pores are sized and configured to allow inflammatory agents in blood or plasma as small as 0.5 nanometers and as large as 600 nanometers to pass through the walls of the hollow fibers.
  • the device 100 further includes an inlet port 3 for receiving unfiltered blood or plasma and an outlet port 4, wherein filtered blood or plasma exits the device for reintroduction into the circulatory system of the individual/patient.
  • an adsorption component 5 refers to a substance which binds, captures, or otherwise adsorbs circulating inflammatory agents.
  • the adsorption component 5 can be activated carbon, non-ionic exchange resins, ion exchange resins, or combinations thereof.
  • the activated carbon can include coated coconut shell granule, uncoated coconut shell granule, and/or synthetic charcoal.
  • the activated carbon may have a pore size distribution of a micropore region of less than 100 Angstroms, a mesopore region of between about 100 and 1 , 000 Angstroms, and a macropore region of greater than 1 ,000 Angstroms.
  • the non-ionic exchange resin can include non-ionic aliphatic ester resins, non-ionic polystyrene divinyl benzene resins, or any other suitable non-biologic adsorptive resin.
  • the non-ionic aliphatic ester resin has an average surface area of approximately 500 m2/g, an average pore size of between about 300-600 Angstroms, and a mean particle diameter of about 560 microns.
  • the non-ionic polystyrene divinyl benzene resin has an average surface area of approximately 700 m2/g, an average pore size of about 300 Angstroms, and a mean particle diameter from approximately 35 microns to approximately 120 microns.
  • the non-ionic polystyrene divinyl benzene resin has an average surface area of approximately 600 m2/g, an average pore size of 100-400 Angstroms, and a mean particle diameter of between about 300 microns to about 500 microns.
  • Adsorption component 5 can be applied to carriers which include, but are not limited, to coated or otherwise treated Alginate-Based Hydrogel Beads, perlite beads, Bio-Beads SM-2 Resin, and Bio-Beads S-X beads, or any suitable carrier as will be appreciated by a person of ordinary skill in the art,
  • the devices, systems and methods described herein support the broad-spectrum reduction of circulating cytokines and CytoVesicles from blood and blood plasma.
  • assays and size exclusion techniques may be implemented to measure cytokine and CytoVesicle levels in blood and plasma prior to implementation of the devices, systems and methods described and then during and after completion of the devices, systems and methods described in the submission.
  • the reduction of toxins and pathogens can be quantified in blood or blood plasma.
  • Access to the circulatory system can be obtained from arterial access or venous access.
  • access is obtained through the insertion of a central venous catheter into a patient.
  • the catheter is a dual lumen catheter 30.
  • a primary solution which may include a saline or albumin solution is advantageously circulated throughout the device to improve hemocompatibility.
  • anticoagulant agents may be administered.
  • the device 10 is configured to connect through the extracorporeal lines of the catheter to the patient’s circulatory system.
  • a pump 20 facilitates flow from the patient’s circulatory system and through the extracorporeal device 10.
  • the pump can be any approved device suitable for facilitating the extracorporeal filtration of blood and/or plasma.
  • Exemplary pumps include dialysis pumps and CRRT machines.
  • the device includes walls of porous hollow-fiber membranes, as described with reference to Figure 2, wherein a formulation of adsorbent components are resident outside of the membrane walls and within the extra-lumen space between the outer shell of the cartridge and the hollow-fibers.
  • the adsorbent components are formulated to bind, capture or adsorb a broad-spectrum of inflammatory particles that pass through the fiber walls to interact with the adsorbent components.
  • the blood or plasma is circulated to flow at rates sufficient to create pressure to cause plasma and inflammatory particles to flow through the fiber walls, but not at rates that would cause hemolysis.
  • the population of inflammatory particles is captured and reduced from the entire bloodstream, which is continuously infused back into the patient at rates equal to its removal during treatment.
  • aspects of the invention are based upon the surprising discovery of a system and method for simultaneously removing circulating cytokines, CytoVesicles, cytokine aggregates, and endotoxins using a single extracorporeal device.
  • Cytokine aggregates refer to two or more cytokines bound together. The removal of circulating cytokines, CytoVesicles, cytokine aggregates, and endotoxins in a single device without harming critical blood components creates considerable therapeutic benefits.
  • a method for treating a disease or disorder caused or exacerbated by a heightened inflammatory response includes providing an adsorptive toxin removal device such as the device described above with reference to Figure 2.
  • the device includes a housing, a hollow fiber plasma filter having a plurality of pores sized between about 200-1500 Angstroms, and a plurality of adsorbents positioned inside the housing and outside the hollow fiber filter.
  • Plasma is filtered through the adsorptive toxin removal device such that inflammatory causing agents having a diameter less than 0.60 microns can pass through the pores of the hollow fiber filter and enter the extra-lumen space.
  • the inflammatory causing agents are exposed to the plurality of adsorbents in the extra-lumen space such that the inflammatory agents are caused to be bound, captured, and/or adsorbed by the adsorbents, thereby reducing the amount of inflammatory causing agents in an individual’s plasma.
  • the inflammatory causing agent can be a circulating cytokine.
  • the circulating cytokine can be IL-1 , TNF-a, IL-6, IL-1 1 , IL-8 and other chemokines, G-CSF, and GM-CSF.
  • TGF-b transforming growth factor-b
  • IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-13 and transforming growth factor-b (TGF-b) and combinations thereof, as well as those contributing to cellular inflammation such as IL-1 , IL-2, IL-3, IL-4, IL-7, IL-9, IL-10, IL-12, interferons (IFNs), IFN-g inducing factor (IGIF), TGF-b, and TNF-a and -b.
  • IFNs interferons
  • IFN-g inducing factor IGIF
  • TGF-b TNF-a and -b.
  • the removal or reduction in the number of inflammatory causing agents in the blood or plasma is useful for the treatment of a wide range of diseases or disorders caused or exacerbated by an abnormal production or dysregulation of pro-inflammatory cytokines.
  • diseases or conditions can include, without limitation, conditions associated with cytokine storm syndrome (CSS), virus induced cytokine storm, bacteria-induced cytokine storm, acute respiratory distress syndrome (ARDS), cytokine release syndrome (CRS), graft-versus-host disease (GVFID), sepsis, systemic inflammatory response syndrome (SIRS), hepatic encephalopathy, acute kidney injury (AKI), severe pneumonia, and combinations thereof.
  • devices and methods described herein are useful for capturing biologic toxins such as endotoxins and exotoxins shed or released by bacteria.
  • the bacteria can be gram negative or gram positive.
  • the reduction in pro-inflammatory cytokines, CytoVesicles, cytokine aggregates, and/or endotoxins can also improve outcomes with respect to organ transplantation.
  • the reduction and/or elimination of circulating inflammatory articles increases viability of donor organs for transplant.
  • the filtration of donor blood to remove pro-inflammatory articles, endotoxin, exotoxin, and the like can purify donor blood prior to infusion into a human recipient.
  • a method for reducing the presence of unwanted drug agents from the bloodstream includes providing an extracorporeal device having a hollow fiber plasma filter and a plurality of adsorbents positioned inside the housing and outside the hollow fibers, filtering blood or plasma through the hollow fiber plasma filter, allowing the unwanted drug agent or agents to pass through the pores of the hollow fiber and into the extra-lumen space, and adsorbing, capturing, or otherwise binding the drug agents to an adsorbent as described herein.
  • the drug agent can be any pharmaceutical agent, illicit drug, controlled substance, or similar compound for which the presence of said drug agent at above a certain threshold level in the blood causes a deleterious effect.
  • Drugs can include, without limitation, acetaminophen, barbiturates, narcotics, and chemotherapeutic agents.
  • assays To quantify the reduction of inflammatory particles from the blood or plasma, assays, size exclusion techniques, and image measurement technologies may be utilized to measure levels of inflammatory particles in patient blood or plasma from a sample of patient blood or plasma taken before and after administration of the therapy.

Landscapes

  • Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Anesthesiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Chemical & Material Sciences (AREA)
  • Water Supply & Treatment (AREA)
  • Cardiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • External Artificial Organs (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

L'invention concerne des dispositifs, des systèmes et des procédés de réduction de grande ampleur des cytokines pro-inflammatoires dans le sang. Les cytokines pro-inflammatoires peuvent circuler librement dans le sang, de même que des cytokines qui sont transportées à l'intérieur de particules dénommées collectivement CytoVésicules ou liées à leur surface, tout en adsorbant simultanément les toxines et les pathogènes du sang et du plasma sanguin. Une colonne de séparation de plasma comportant des composants de liaison, de capture et d'adsorption optimisent l'élimination des cytokines et des CytoVésicules du sang tout en réduisant au minimum l'élimination d'éléments sanguins essentiels. Des composants adsorbants sont incorporés à l'intérieur de l'espace hors lumière, à l'extérieur des parois des fibres plasmatiques et à l'intérieur de l'enveloppe externe de la colonne, et peuvent comprendre du charbon actif, des résines échangeuses d'ions et des résines échangeuses non ioniques. Les dispositifs, systèmes et procédés obtenus atténuent les symptômes ou la gravité d'un large éventail de pathologies associées à une production anormale de cytokines pro-inflammatoires ou à un dérèglement de celles-ci.
PCT/US2020/044223 2019-08-01 2020-07-30 Dispositifs, systèmes et procédés de réduction de grande ampleur des cytokines pro-inflammatoires dans le sang Ceased WO2021022023A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP20757445.0A EP4007618A1 (fr) 2019-08-01 2020-07-30 Dispositifs, systèmes et procédés de réduction de grande ampleur des cytokines pro-inflammatoires dans le sang
CA3148773A CA3148773A1 (fr) 2019-08-01 2020-07-30 Dispositifs, systemes et procedes de reduction de grande ampleur des cytokines pro-inflammatoires dans le sang
JP2022506670A JP2022542517A (ja) 2019-08-01 2020-07-30 血液中の炎症促進性サイトカインの広範囲にわたる減少のためのデバイス、システム及び方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962881740P 2019-08-01 2019-08-01
US62/881,740 2019-08-01

Publications (1)

Publication Number Publication Date
WO2021022023A1 true WO2021022023A1 (fr) 2021-02-04

Family

ID=72088376

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/044223 Ceased WO2021022023A1 (fr) 2019-08-01 2020-07-30 Dispositifs, systèmes et procédés de réduction de grande ampleur des cytokines pro-inflammatoires dans le sang

Country Status (5)

Country Link
US (2) US20210030942A1 (fr)
EP (1) EP4007618A1 (fr)
JP (1) JP2022542517A (fr)
CA (1) CA3148773A1 (fr)
WO (1) WO2021022023A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3214888A1 (fr) * 2021-04-21 2022-10-27 James A. Joyce Adsorption extra-lumiere d'agents pathogenes viraux du sang
US12053567B2 (en) 2021-12-27 2024-08-06 Santersus Ag Method and device for removal of circulating cell free DNA
CN114854579A (zh) * 2022-04-13 2022-08-05 武汉大学 可用于临床的外周血特定亚群细胞外囊泡分离平台

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4013564A (en) * 1975-03-17 1977-03-22 Takeda Chemical Industries, Ltd. Multipurpose metabolic assist system
WO1993002777A1 (fr) * 1991-07-26 1993-02-18 Research Medical, Inc. Systeme de sorbants pour filtre de plasma servant a extraire des constituants du sang et systeme de transport de masse ameliore
WO2014079681A2 (fr) * 2012-11-26 2014-05-30 Gambro Lundia Ab Système de support de foie
WO2017129773A1 (fr) * 2016-01-27 2017-08-03 Bellco S.R.L. Filtre de purification de sang
WO2018183072A1 (fr) * 2017-03-27 2018-10-04 Cytosorbents Corporation Procédés d'élimination de toxines du sang à l'aide d'un circuit extracorporel constitué d'un module de filtre à fibres creuses et d'un sorbant polymère associé

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020146413A1 (en) * 2001-04-10 2002-10-10 James Brady System for treating patient with bacterial infections
US8329388B2 (en) * 1997-07-30 2012-12-11 Cytosorbents, Inc. Biocompatible devices, systems, and methods for reducing levels of proinflammatory of antiinflammatory stimulators or mediators in the blood
US20020197252A1 (en) * 2001-04-10 2002-12-26 Renal Tech International Selective adsorption devices and systems
US6733827B2 (en) * 2001-04-11 2004-05-11 The Procter & Gamble Co. Processes for manufacturing particles coated with activated lignosulfonate
WO2003055545A1 (fr) * 2001-12-25 2003-07-10 Kaneka Corporation Adsorbant de cytokine, procede d'elimination par adsorption et appareil correspondant
DE10258944A1 (de) * 2002-12-17 2004-07-01 B. Braun Medizintechnologie Gmbh Vorrichtung zur Entfernung von bakteriellen Lipopolysacchariden oder/und Lipoteichonsäuren aus proteinhaltigen Flüssigkeiten sowie deren Verwendung zur Behandlung von Sepsis
US8038638B2 (en) * 2004-02-23 2011-10-18 Hemolife Medical, Inc. Plasma detoxification and volume control system and methods of use
US20050281809A1 (en) * 2004-02-23 2005-12-22 Roberts Craig P Plasma detoxification and volume control system and methods of use
PL2735360T3 (pl) * 2012-11-26 2017-09-29 Gambro Lundia Ab Urządzenie adsorbujące łączące granulki i membrany z włókien kanalikowych
KR102300302B1 (ko) * 2013-02-12 2021-09-09 도레이 카부시키가이샤 혈액 정화 컬럼
EP3173145B1 (fr) * 2014-07-22 2022-09-07 Asahi Kasei Medical Co., Ltd. Adsorbant pour éliminer de l'histone et dispositif de purification pour liquide issu d'organisme vivant
GB201512468D0 (en) * 2015-07-16 2015-08-19 C Tex Ltd And University Of Brighton Shaped nanoporous bodies
KR102624853B1 (ko) * 2015-07-30 2024-01-12 나가세케무텍쿠스가부시키가이샤 내독소 흡착제
EP3422943A4 (fr) * 2016-03-02 2019-10-16 ExThera Medical Corporation Méthode de traitement d'intoxication médicamenteuse
WO2017205720A1 (fr) * 2016-05-26 2017-11-30 Drexel University Matériaux en graphite à surface ouverte pour l'adsorption de cytokines dans le sang
EP3290067B1 (fr) * 2016-09-06 2021-03-03 Gambro Lundia AB Appareil d'assistance hépatique
US11135566B2 (en) * 2017-04-04 2021-10-05 Toray Industries, Inc. Porous fiber and adsorption column
CN110944746A (zh) * 2017-07-26 2020-03-31 沙特基础工业全球技术有限公司 复合吸附剂、装置和方法
US20190117869A1 (en) * 2017-10-24 2019-04-25 DD Innovations Lab, LLC Apparatus and methods to remove toxins from blood by plasmapheresis
ES3020757T3 (en) * 2017-11-22 2025-05-23 Hdl Therapeutics Inc Methods for priming fluid circuits of a plasma processing system
CN112203758B (zh) * 2018-07-31 2022-12-23 东丽株式会社 用于吸附有机物的载体

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4013564A (en) * 1975-03-17 1977-03-22 Takeda Chemical Industries, Ltd. Multipurpose metabolic assist system
WO1993002777A1 (fr) * 1991-07-26 1993-02-18 Research Medical, Inc. Systeme de sorbants pour filtre de plasma servant a extraire des constituants du sang et systeme de transport de masse ameliore
WO2014079681A2 (fr) * 2012-11-26 2014-05-30 Gambro Lundia Ab Système de support de foie
WO2017129773A1 (fr) * 2016-01-27 2017-08-03 Bellco S.R.L. Filtre de purification de sang
WO2018183072A1 (fr) * 2017-03-27 2018-10-04 Cytosorbents Corporation Procédés d'élimination de toxines du sang à l'aide d'un circuit extracorporel constitué d'un module de filtre à fibres creuses et d'un sorbant polymère associé

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GLOBAL, REGIONAL, AND NATIONAL SEPSIS INCIDENCE AND MORTALITY, 1990-2017: ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY, January 2020 (2020-01-01)

Also Published As

Publication number Publication date
US20240424183A1 (en) 2024-12-26
CA3148773A1 (fr) 2021-02-04
JP2022542517A (ja) 2022-10-04
US20210030942A1 (en) 2021-02-04
EP4007618A1 (fr) 2022-06-08

Similar Documents

Publication Publication Date Title
US20240424183A1 (en) Devices, systems and methods for the broad-spectrum reduction of pro-inflammatory cytokines in blood
Ankawi et al. A new series of sorbent devices for multiple clinical purposes: current evidence and future directions
AU2010326028B2 (en) Method for removing cytokines from blood with surface immobilized polysaccharides
US8038638B2 (en) Plasma detoxification and volume control system and methods of use
CA2644732C (fr) Filtre pouvant etre regenere utilise dans le traitement extracorporeal de liquides contenant des particules et leur utilisation
AU2012364760B2 (en) Cartridge and method for increasing myocardial function
EP1765433B1 (fr) Systeme de detoxification du plasma et de regulation du volume sanguin
CN101657224B (zh) 用于净化血液的组件
AU2018246007A1 (en) Methods for removal of toxins from blood using an extracorporeal circuit comprised of a hollow-fiber filter module and polymer sorbent in combination
US20220273855A1 (en) Device and method for preparing a donor organ for transplantation
ES2391849T3 (es) Diálisis de bioquivalencia
US20230036583A1 (en) Devices and methods for reducing rejection of a transplanted organ in a recipient
JP2017525489A (ja) 炎症性メディエーター並びに顆粒球及び単球を血液から除去するためのシステム
EP3024510A1 (fr) Systèmes et dispositifs de purification du sang comprenant un fluide de remplacement produit en interne
Rogiers Hemofiltration and Plasmapheresis
US20240399045A1 (en) Extra-lumen adsorption of viral pathogens from blood
ter Beek et al. Advanced Blood Purification Therapies
de Sousa Investigation of dual layer hollow fiber mixed matrix membranes characteristics for toxin removal from blood
Srisawat Extracorporeal Blood Purification Therapy for Sepsis
Murray et al. Pharmacist
AU2014277852A1 (en) Method for removing cytokines from blood with surface immobilized polysaccharides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20757445

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3148773

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2022506670

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020757445

Country of ref document: EP

Effective date: 20220301